We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Advanced Technique Diagnoses Lyme Disease Early

By LabMedica International staff writers
Posted on 06 May 2013
Patients who contract Lyme disease need a quick diagnosis so that essential treatment can begin to avoid long-term complications.

The diagnostic process may be delayed if a physician does not recognize a skin rash caused by Lyme disease because it does not have the bull's-eye appearance that is best known to physicians and the public.

Scientists at University of Medicine and Dentistry of New Jersey (UMDNJ; Newark, NJ, USA) working with others, enrolled 14 patients in an ongoing prospective trial which includes an advanced diagnostic technique that employs a selective amplification of DNA from Borrelia burgdorferi, the spirochete that causes Lyme disease. More...
This technique uses electrospray ionization mass spectrometry and isothermal amplification. This is then followed by polymerase chain reaction (PCR) testing, all designed to detect even small numbers of multiple strains of the Lyme agent. The patients were all over 18 years of age and lived in suburban Baltimore (MD, USA), where Lyme disease is endemic.

Unlike existing methods used to diagnose Lyme disease, the novel experimental technique is able to detect evidence of B. burgdorferi early, even in cases where the bacterium is still at low levels in the bloodstream, and sooner than traditional antibody tests, which may require several weeks before becoming positive. It also is able to distinguish between new infections and prior exposure to B burgdorferi.
Of the patients analyzed, ten were identified by the experimental technique to have strong microbiologic evidence of Lyme disease although they had presented with skin lesions that differed markedly from the classic bull's-eye pattern. The authors noted that “This emphasis on target-like lesions may have inadvertently contributed to an under appreciation for atypical skin lesions caused by Lyme disease." PCR of skin biopsy samples may provide insight as to whether a negative blood PCR is the result of infection with a skin-restricted strain in patients in whom bacterial dissemination is not expected or a result of low copy number of B. burgdorferi in the blood sample.

Steven E, Schutzer, MD, the senior author of the study, said, “Doctors who see a rash in a patient who has been in an area where Lyme disease frequently occurs should be alert to the fact that the Lyme disease rash does not have to look like a bull's-eye, ring-within-a ring, known as erythema migrans. The rash may look different. Doctors should search carefully both for other signs that might suggest Lyme disease, such as flu-like symptoms, and equally for signs that may point towards other conditions. Early diagnosis of most diseases gives the best chance for a cure. This is especially true for Lyme disease." The report was published in the May 2013 issue of the journal Emerging Infectious Diseases.

Related Links:
University of Medicine and Dentistry of New Jersey


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.